{"id":"W4361814644","doi":"10.1158/1078-0432.c.6531017.v1","title":"Data from Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada); BC Cancer Agency; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"National Institutes of Health","keywords":"Medicine; Refractory (planetary science); Lymphoma; Chills; Gastroenterology; Internal medicine; Clinical endpoint; Adverse effect; Rituximab; Nivolumab; Phases of clinical research; Toxicity; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002206816,0.0009563718,0.001712958,0.000263788,0.0004333782,0.001030516,0.0006161169,0.0008428146,0.005051155],"category_scores_gemma":[0.0018229,0.0003574438,0.001506357,0.0005361341,0.0003759185,0.0007327421,0.0002476703,0.002080661,0.001266581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006513713,"about_ca_system_score_gemma":0.001156108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00093068,"about_ca_topic_score_gemma":0.002579723,"domain_scores_codex":[0.9993703,0.0003188106,0.00006711424,0.00007294742,0.0001053082,0.00006559007],"domain_scores_gemma":[0.9984798,0.0004395387,0.0003542018,0.0001908597,0.0001867328,0.0003488192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5856085,0.01956171,0.02169435,0.004424999,0.006425795,0.0006059104,0.0004034291,0.006078488,0.05712692,0.0006851661,0.05036641,0.2470183],"study_design_scores_gemma":[0.58417,0.2716249,0.06681425,0.000574063,0.005466168,0.001293186,0.0001863228,0.002472076,0.0140698,0.0008140187,0.0524137,0.0001016137],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"dataset","genre_scores_codex":[0.919759,0.0228385,0.002810683,0.00226431,0.0005203186,0.005015405,0.02387929,0.0003960297,0.02251644],"genre_scores_gemma":[0.9479427,0.008240841,0.001925197,0.003775938,0.0002982804,0.003558564,0.02864907,0.0001265251,0.005482782],"genre_candidate":"dataset","genre_consensus":null,"teacher_disagreement_score":0.005051155,"threshold_uncertainty_score":0.01689786,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.078055831353935,"score_gpt":0.3054869811184105,"score_spread":0.2274311497644755,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}